摘要
目的 :对大肠癌术后早期应用奥沙利铂 (乐沙定 )联合 5 FU/甲酰四氢叶酸辅助化疗的安全性进行探讨 .方法 :将 36例行根治术的Ⅲ期大肠癌患者随机分为 2组 ,治疗组于术后第 4日开始应用奥沙利铂联合 5 FU/甲酰四氢叶酸辅助化疗 ,观察患者化疗反应情况、术后切口愈合状况和血清IL 2 ,sIL 2R的变化 ,对照组不做化疗 .结果 :两组切口愈合状况无明显差异 ,化疗组有少数患者出现恶心、欲吐现象 ,经对症处理后症状基本消失 ,白细胞水平下降不显著 ,术后两组IL 2和sIL 2R的变化趋势相同 .结论 :大肠癌术后早期应用奥沙利铂联合 5 FU/甲酰四氢叶酸辅助化疗 ,不会影响患者切口愈合能力和增加术后并发症 ,对患者的免疫功能影响不大 ,对延长大肠癌患者的生存期 ,延缓术后复发可能会起到积极的作用 .
AIM: To investigate the safety of early application of adjuvant chemotherapy, oxaliplatin combined with 5 FU/leucovorin, in patients with colorectal cancer after radical colorectomy. METHODS: Thirty six patients with colorectal cancer were randomized into two study groups. The treatment group received adjuvant chemotherapy using oxaliplatin combined with 5 FU/leucovorin on the 4 th day after colorectomy; while the control group did not receive adjuvant chemotherapy. The tolerances of chemotherapy, the impact on wound healing, and the change of IL 2, sIL 2R in serum were determined. RESULTS: The healing condition of wound showed no significant difference between two groups. Chemotherapy induced nausea and vomiting was reported in small numbers of patients in the treatment group, but was well controlled after anti emetic therapy. Neutropenia was not reported either in treatment group or control group. In addition, both groups showed the same change of IL 2 and sIL 2R. CONCLUSION: Early application of adjuvant chemotherapy using oxaliplatin combined with 5 FU/leucovorin is beneficial to the patients with colorectal cancer who have underwent radical colorectomy. It has no influence on the patients healing ability and will not increase the incidence of subsequent symptoms after operation. Furthermore, adjuvant chemotherapy doesn't influence patients immune system and then will not reduce the body's antineoplastic ability. Futhermore, early application of adjuvant chemotherapy in patients after colorectomy can positively prolong the survival time and delay the recurrence.
出处
《第四军医大学学报》
北大核心
2003年第20期1890-1892,共3页
Journal of the Fourth Military Medical University
